Cullinan Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(49,661) | $(48,501) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Equity-based compensation expense | 7,616 | 9,374 |
| Accretion on marketable securities | (777) | (2,311) |
| Depreciation and amortization | 79 | 76 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (662) | 1,742 |
| Accounts payable | 1,667 | 1,720 |
| Accrued expenses and other liabilities | (4,307) | (5,255) |
| Net cash used in operating activities | (46,045) | (43,155) |
| Investing activities: | ||
| Maturities of marketable securities | 52,549 | 162,645 |
| Purchases of marketable securities | (20,135) | (125,840) |
| Net cash provided by investing activities | 32,414 | 36,805 |
| Financing activities: | ||
| Issuance of common stock under equity-based compensation plans | 380 | — |
| Net cash provided by financing activities | 380 | — |
| Net decrease in cash and cash equivalents | (13,251) | (6,350) |
| Cash and cash equivalents at beginning of period | 88,332 | 83,005 |
| Cash and cash equivalents at end of period | $75,081 | $76,655 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.